DMT is not without risk, but it has a relatively wide margin between an active dose and a lethal one. Animal studies suggest the lethal dose is roughly 20 to 50 times higher than a typical ceremonial dose, and no documented human death has been attributed to DMT alone. Every fatality in the published literature involved other substances. That said, “not usually fatal” is a low bar for safety. DMT carries real cardiovascular, psychological, and drug-interaction risks that depend heavily on who is using it and how.
Short-Term Physical Effects
DMT raises blood pressure and heart rate within minutes of administration. In clinical studies, peak systolic blood pressure has reached as high as 159 mmHg, with diastolic readings near 98 mmHg and heart rates climbing to 119 beats per minute. These spikes are rapid, especially with injected or inhaled forms, typically peaking within two minutes. In most healthy participants, these changes are temporary and resolve as the drug wears off.
For someone with no cardiovascular issues, these transient bumps are generally not dangerous. But for anyone with high blood pressure, a heart condition, or risk factors for stroke, even a short-lived spike into that range could be medically significant. One clinical trial participant experienced a serious event involving an abnormally slow heart rate paired with a sudden drop in blood pressure after receiving a moderate dose.
How Long It Lasts
When smoked or vaporized, DMT acts fast and clears fast. The experience typically begins within seconds, peaks within a few minutes, and largely resolves in 15 to 30 minutes. Animal pharmacokinetic data shows an intranasal half-life of roughly 12 to 14 minutes, consistent with the short duration users report.
Ayahuasca, which contains DMT alongside plant-based compounds that prevent its breakdown in the gut, is a different story. The experience lasts several hours because those companion compounds (MAO inhibitors) keep DMT circulating in the bloodstream far longer. This extended duration also extends the window for adverse effects, particularly nausea, vomiting, and cardiovascular changes.
Brain Toxicity
DMT does not appear to be neurotoxic. Early concerns about potential brain damage have not been supported by subsequent research, and some studies now suggest DMT may actually have neuroprotective properties. Long-term ayahuasca users do show measurable structural differences in certain brain regions compared to non-users on MRI scans, but these changes have not been linked to cognitive impairment or damage.
In clinical trials involving both DMT and the closely related compound 5-MeO-DMT, no safety signals have emerged on cognitive function testing. Across studies totaling 78 participants, no serious adverse events were reported, no one dropped out, and nearly all side effects were mild. The most common complaints were headache, nausea, and nasal discomfort (in studies using intranasal delivery).
Psychological Risks
The most significant safety concern with DMT is psychiatric, not physical. Like other psychedelics, DMT can trigger psychotic episodes in people who are vulnerable to them. The research is consistent on this point: individuals with a personal or family history of schizophrenia, other psychotic disorders, or manic episodes are at meaningfully elevated risk of a severe adverse reaction.
This isn’t limited to people who’ve already been diagnosed. A family history of psychosis, even in a first-degree relative, appears to increase susceptibility. The recommendation from researchers who have studied this extensively is unambiguous: people with any personal or family history of psychotic illness or mania should not use DMT or ayahuasca.
Even in people without these risk factors, DMT can produce intense anxiety, confusion, and distressing hallucinations during the acute experience. Clinical trials manage this with trained support staff and controlled environments. Outside that setting, a frightening experience can lead to panic, dangerous behavior, or lasting psychological distress.
Lingering Visual Effects
Some psychedelic users develop persistent visual disturbances after use, a condition known as hallucinogen persisting perception disorder (HPPD). In one study tracking psychedelic users over four weeks, about a third reported at least one HPPD-type symptom, such as visual snow, trailing images, or halos around objects. The reassuring finding: fewer than 1% of the total sample found these effects distressing. For most people who notice them, the symptoms are mild and more of a curiosity than a problem. Still, for a small number of users, these visual changes persist and cause real disturbance.
Dangerous Drug Interactions
The most life-threatening risk associated with DMT involves combining it with certain medications, particularly antidepressants. DMT acts on serotonin receptors, and when serotonin levels build up too high in the brain, the result is serotonin syndrome, a potentially fatal condition involving dangerously high body temperature, seizures, and organ failure.
This risk is especially acute with ayahuasca. The MAO-inhibiting compounds in the brew block one of the body’s key pathways for breaking down serotonin. If someone is also taking an SSRI or SNRI antidepressant (common medications like fluoxetine, sertraline, citalopram, or paroxetine), both serotonin production and serotonin clearance are affected simultaneously. At least one documented case involved symptoms of serotonin toxicity after ayahuasca use in someone taking fluoxetine. Combining ayahuasca with any serotonergic medication is considered dangerous.
Pure DMT that is smoked or vaporized (without MAO inhibitors) carries a lower interaction risk, but it still acts on serotonin pathways, and caution with serotonergic medications remains warranted.
Seizure Risk
Psychedelics, including DMT, have a documented association with seizures, though it’s uncommon. Poison control data shows seizures reported in about 2.2% of ayahuasca cases. The risk appears to be concentrated in people with existing epilepsy or a family history of seizure disorders. In one survey of psychedelic users who reported associated seizures, more than half had a personal history of epilepsy and the majority had a family history. Clinical evidence suggests psychedelics lower the threshold for a person’s typical seizure pattern rather than creating seizures through a completely new mechanism.
Purity and Preparation
Outside of clinical trials, there is no quality control over DMT. Street or self-extracted DMT may contain residual solvents from the extraction process, unknown adulterants, or inconsistent concentrations. Every documented DMT-associated death in the literature involved other substances alongside DMT. Whether those substances were intentionally co-ingested or present as contaminants, the pattern underscores that the unregulated supply itself is a major variable in real-world safety. Dose consistency is also a practical problem: without lab testing, users have no reliable way to know the potency of what they have, making accidental high doses a real possibility.
Who Faces the Most Risk
DMT’s safety profile depends less on the compound itself and more on the person using it. The groups with clearly elevated risk include:
- People with psychotic disorders or a family history of psychosis, who face the possibility of triggered or worsened psychotic episodes
- People taking SSRI, SNRI, or MAOI medications, who risk serotonin syndrome, particularly with ayahuasca
- People with cardiovascular conditions, who may not tolerate the acute spikes in blood pressure and heart rate
- People with epilepsy or a family history of seizures, who appear to have a lowered seizure threshold during use
For a healthy person with no psychiatric vulnerabilities, no relevant medications, and no cardiovascular or neurological conditions, DMT in a controlled dose carries a low risk of serious physical harm. But “low risk” is not “no risk,” and the intense, disorienting nature of the experience introduces unpredictability that clinical safety data alone cannot fully capture.